John R Ingram
Cardiff University
H-index: 35
Europe-United Kingdom
Top articles of John R Ingram
A systematic review of 454 randomized controlled trials using the Dermatology Life Quality Index: experience in 69 diseases and 43 countries
2024/3
John R Ingram
H-Index: 24
Mapping of Family Reported Outcome Measure (FROM-16) scores to EQ-5D: algorithm to calculate utility values
Quality of Life Research
2024/2/25
The Global Hidradenitis Suppurativa Atlas (GHiSA) methodology: Combining global proportions in a pooled analysis
Dermatology (Basel, Switzerland)
2024/2/14
Afsaneh Alavi
H-Index: 27
John R Ingram
H-Index: 24
Protocol of a scoping review of outcome domains in dermatology
2024/2/1
John R Ingram
H-Index: 24
Murad Alam
H-Index: 41
Electronic Patient-Reported Outcomes in Hidradenitis Suppurativa: Content Validity and Usability of the Electronic Hidradenitis Suppurativa Symptom Daily Diary, Hidradenitis …
Dermatology
2024/2
John R Ingram
H-Index: 24
Burden of hidradenitis suppurativa: a systematic literature review of patient reported outcomes
2024/1/6
John R Ingram
H-Index: 24
Anne-Mary Lewis-Mikhael
H-Index: 10
Inclusive and equitable language for skin colour in the British Journal of Dermatology: acknowledging our past and laying the foundations to move forward
2024/5
Feasibility of daily pain measurement using text messages in hidradenitis suppurativa clinical trials; data from the THESEUS study
British Journal of Dermatology
2024/5
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: A Danish nationwide cohort study
British Journal of Dermatology
2024/5
Brian Kirby
H-Index: 18
John R Ingram
H-Index: 24
Measurement of the major ignored burden of multiple myeloma, pernicious anaemia and of other haematological conditions on partners and family members: A cross‐sectional study
European Journal of Haematology
2024/4/5
Global consensus process to establish a core dataset for hidradenitis suppurativa registries
British Journal of Dermatology
2024/4
Responsiveness and minimal important change of the Family Reported Outcome Measure (FROM-16)
Healthcare
2023/9/26
Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo …
SKIN The Journal of Cutaneous Medicine
2024/3/18
John R Ingram
H-Index: 24
Methodological innovations and stakeholder involvement in core outcome sets for skin diseases: a survey of the C3 working groups
Archives of Dermatological Research
2024/3/18
John R Ingram
H-Index: 24
Murad Alam
H-Index: 41
Clinical relevance and uptake of core outcome sets in dermatology
Archives of Dermatological Research
2024/3
John R Ingram
H-Index: 24
Murad Alam
H-Index: 41
Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): a prospective cohort study
British Journal of Dermatology
2024/3
Addressing high placebo response rates in randomized clinical trials for hidradenitis suppurativa
British Journal of Dermatology
2024/3
John R Ingram
H-Index: 24
MSR15 Psychometric Validation of the Electronic Hidradenitis Suppurativa (HS) Symptom Daily Diary (eHSSDD) and Electronic HS Symptom Questionnaire (eHSSQ) Using Data from the …
Value in Health
2023/6/1
MSR64 Psychometric Validation of the Electronic Hidradenitis Suppurativa Quality of Life (eHiSQOL) Questionnaire Using Pooled Data from the Phase 3 BE HEARD Trials of …
Value in Health
2023/6/1
Validation of the Hidradenitis Suppurativa Investigator Global Assessment: a novel hidradenitis suppurativa–specific investigator global assessment for use in interventional trials
JAMA dermatology
2023/6/1
John R Ingram
H-Index: 24
